Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG Vaccination for Pre-symptomatic Alzheimer's Disease
NCT06078891Phase 1Enrolling by invitation
- Start
- Jul 2023
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bcg vaccine in Alzheimer's disease (AD). Primary endpoint: Plasma phosphorylated Tau (p-tau181) biomarker level at 1.5 years. Started Jul 2023; status: enrolling by invitation.
02
Drugs
bcg vaccine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06078891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078891.